ArticleScientific reports2022
High expression of lncRNA PELATON serves as a risk factor for the incidence and prognosis of acute coronary syndrome.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- LncRNAs as Emerging Diagnostic Biomarkers for Cardiovascular Diseases: Evidence Synthesis Through Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Serum long non-coding RNA SNHG9 as a diagnostic biomarker for acute coronary syndrome and a predictor of prognosis following percutaneous coronary intervention: a clinical evaluation.Journal of cardiothoracic surgery · 2026Article
- Silencing of lncRNA TFAP2A-AS1 attenuates the development of acute coronary syndrome by inhibiting TFAP2A expression.Biomedical reports · 2026Article
- LncRNA HYMAI Promotes Endothelial Cell Autophagy via miR-19a-3p/ ATG14 to Attenuate the Progression of Coronary Atherosclerotic Disease.Current medicinal chemistry · 2026Article
- Exosomal Long Noncoding RNA H19 as a Biomarker and Therapeutic Target in Atrial Fibrillation.International journal of biological sciences · 2026Article
- TheCurrent issues in molecular biology · 2025Article
- Diagnostic lncRNA biomarkers and immune-related ceRNA networks for osteonecrosis of the femoral head in metabolic syndrome identified by plasma RNA sequencing and machine learning.Frontiers in immunology · 2025Article
- Long non-coding RNA SNHG7 serves as a diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after percutaneous coronary intervention.Journal of cardiothoracic surgery · 2024Article
- HAND2-AS1 associates with outcomes of acute coronary syndrome and regulates cell viability of vascular endothelial cells.Irish journal of medical science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is the primary origin of acute coronary syndrome (ACS) diseases. Previous studies have shown that lncRNA plaque-enriched long noncoding RNA in atherosclerotic macrophage regulation (lncRNA PELATON) is a specific lncRNA in macrophage nuclei. This study aims to identify serum lncRNA PELATON as a biomarker for assessing the incidence and prognosis of ACS. Levels of serum lncRNA PELATON were detected by real-time polymerase chain reaction (RT-PCR) in patients with ACS and healthy individuals. The clinical significance of lncRNA PELATON in patients with ACS was assessed by analyzing receiver operating characteristic and survival curves. The serum levels of lncRNA PELATON in patients with ACS were significantly higher than those in healthy individuals. LncRNA PELATON expression was positively correlated with the expression levels of high sensitivity C-reactive protein (hs-CRP), cardiac troponin T (cTnT) and creatine kinase MB (CK-MB) (p < 0.05). LncRNA PELATON can be used as a potential diagnostic index with an AUC of 0.706 for unstable angina pectoris (UA), 0.782 for acute non-ST-segment elevation myocardial infarction (NSTEMI) and 0.900 for acute ST-segment elevation myocardial infarction (STEMI). The incidence of major cardiovascular events in patients with ACS with high lncRNA PELATON expression was higher than that in those with low lncRNA PELATON expression. However, the mortality between patients in the high and low lncRNA PELATON groups was not significantly different. This study showed that higher levels of lncRNA PELATON were negatively correlated with the prognosis of ACS, revealing the potential of this measurement to serve as an index to assess the incidence and prognosis of ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.